Compare Edison International Common Stock (EIX) vs Maravai LifeSciences Holdings Inc. Class A Common Stock (MRVI) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Edison International Common Stock vs Maravai LifeSciences Holdings Inc. Class A Common Stock — how do they compare? Edison International Common Stock trades at $55.49 (market cap $21.35B), while Maravai LifeSciences Holdings Inc. Class A Common Stock trades at $6.56 (market cap $972.90M). The key difference: Edison International Common Stock is far larger — about 21.9× Maravai LifeSciences Holdings Inc. Class A Common Stock's market cap, and Edison International Common Stock pays a 6.33% dividend while Maravai LifeSciences Holdings Inc. Class A Common Stock pays none. Which is the better fit depends on your goals — on Pluang, investors hold Edison International Common Stock for 4 Days and Maravai LifeSciences Holdings Inc. Class A Common Stock for 0 Days on average.
| EIX | MRVI | |
|---|---|---|
Market Cap | $21.35B | $972.90M |
Volume | 15,485,731 | 4,325,710 |
Sector | Utilities | Health |
52-Week High | $80.38 | $9.00 |
52-Week Low | $51.47 | $2.83 |
Typical Hold Time | 4 Days | 0 Days |
Enterprise Value | $64.73B | $1.08B |
Dividend Yield | 6.33% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Edison International (EIX) trades at $55.48, down 0.29% on the day, with a bullish technical signal despite mixed oscillators. The stock offers a high dividend yield of 6.4% and trades below the consensus price target of $59.29. Recent earnings have consistently beaten estimates, with Q3 2026 results pending. However, the stock faces headwinds from unresolved California wildfire liability risks, contributing to a 23% decline in late August 2026.
EIX presents a value opportunity with low P/E (5.73) and P/B (1.22) ratios, strong profitability (ROE 23.06%), and a stable dividend. Key risks include regulatory uncertainty around wildfire costs and a projected decline in 2026 net margin. Analyst sentiment is mixed but leans positive, with 40.5% buy ratings. The stock's upside depends on regulatory clarity and sustained earnings growth.
Maravai LifeSciences (MRVI) trades at $6.53, down 7.51% in the last session amid mixed signals. The stock shows improving fundamentals with Q2 2026 revenue growth of 9% and three consecutive earnings beats, though it remains unprofitable with a -37.07% net margin. Technical analysis indicates neutral positioning with key support at $6 and resistance at $7. Recent news highlights patent expansions in China and institutional accumulation.
The outlook remains cautiously optimistic with analyst consensus pointing to 7% upside potential to the $7.00 price target. Key opportunities include margin expansion and RNA technology leadership, while risks center on persistent cash burn and competitive pressures in life sciences. The stock offers speculative growth potential for risk-tolerant investors.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
About Edison International Common Stock
Edison International is the parent company of Southern California Edison, an electric utility that supplies and delivers electricity across Southern California. It also owns Trio, an energy advisory business.
Read more on EIX →About Maravai LifeSciences Holdings Inc. Class A Common Stock
Maravai LifeSciences Holdings Inc. is a life sciences company supporting drug therapy, diagnostic, and vaccine development through four operating brands: TriLink BioTechnologies (nucleic acid and mRNA synthesis), Cygnus Technologies (biologics safety testing), Glen Research (oligonucleotide synthesis materials), and Alphazyme (enzyme manufacturing). It serves biotech and biopharma customers from discovery through commercial manufacturing.
Read more on MRVI →
